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Abstract
Background: Efficient delivery of anticancer chemotherapies such as paclitaxel (PTX) can improve treatment
strategy in a variety of tumors such as breast and ovarian cancers. Accordingly, researches on polymeric
nanomicelles continue to find suitable delivery systems. However, due to biocompatibility concerns, a few micellar
nanoformulations have exquisitely been translated into clinical uses. Here, we report the synthesis of novel water-
soluble nanomicelles using bioactive polyurethane (PU) polymer and efficient delivery of PTX in the human breast
cancer MCF-7 cells.
Results: The amphiphilic polyurethane was prepared through formation of urethane bounds between hydroxyl
groups in poly (tetramethylene ether) glycol (PTMEG) and dimethylol propionic acid with isocyanate groups in
toluene diisocyanate (TDI). The free isocyanate groups were blocked with phenol, while the free carboxyl groups of
dimethylol propionic acid were reacted with triethylamine to attain ionic centers in the polymer backbone. These
hydrophobic PTMEG blocks displayed self-assembly forming polymeric nanomicelles in water. The PTX loaded PU
nanomicelles showed suitable physical stability, negative zeta potential charge (-43) and high loading efficiency
(80%) with low level of critical micelle concentration (CMC). In vitro drug release profile showed a faster rate of
drug liberation at pH 5.4 as compared to that of pH 7.4, implying involvement of a pH-sensitive mechanism for
drug release from the nanomicelles. The kinetic of release exquisitely obeyed the Higuchi model, confirming
involvement of diffusion and somewhat erosion at pH 5.4. These nanomicelles significantly inhibited the growth
and proliferation of the human breast cancer MCF-7 cells, leading them to apoptosis. The real time RT-PCR analysis
confirmed the activation of apoptosis as result of liberation of cytochrome c in the cells treated with the PTX
loaded PU nanomicelles. The comet assay analysis showed somewhat DNA fragmentation in the treated cells.
Conclusions: Based upon these findings, we propose that the bioactive waterborne polyurethane nanomicelles
can be used as an effective nanocarrier for delivery of anticancer chemotherapies such as paclitaxel.
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Background
Paclitaxel is an anticancer drug that has successfully
been used against a variety of tumors such as ovarian
and breast cancers [1]. It is a lipophilic agent with lim-
ited solubility in water (0.3 μg/ml) [2], thus the most
available injectable formulation of paclitaxel (i.e.,
Taxol
®) has been formulated using mixture of Cremo-
phor EL and ethanol (1:1 v/v).H o w e v e r ,s u c hf o r m u l a -
tion was reported to induce serious undesired adverse
reactions such as neurotoxicity and anaphylactic reac-
tions due to high amount of Cremophor EL [3] that can
also alter the pharmacokinetics of PTX [4].
So far, various formulations of PTX have been devel-
oped to enhance the aqueous solubility of PTX and to
obtain suitable delivery system for controlled release
and/or targeted delivery of PTX [5-9]. Of these,
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nanocarriers (50-200 nm) with an efficient loading and
solubilizing potential were shown to accumulate in
tumor microenvironment through enhanced permeation
and retention (EPR) effects [5,6,10]. Having exploited
passive targeting strategy based on EPR effects, the
major objectives of these studies were to achieve a bet-
ter pharmacokinetic profile with maximum efficiency in
cancer cells and minimum toxicity in normal cells/
tissue.
For Cremophor EL-free micellar formulation of
paclitaxel, various block copolymers have been pre-
viously exploited including: diblock copolymer meth-
oxy poly(ethylene glycol)-block-poly (D, L-lactic acid)
[11], methoxy poly(ethylene glycol)-block-poly(capro-
lactone) [12,13], chitosan-poly(epsilon-caprolactone)-
poly(ethylene glycol) [9], chitosan-poly(epsilon-capro-
lactone)-poly(ethylene glycol) graft copolymers [9],
hydrotropic oligomer-glycol chitosan [14], cyclic RGD
conjugated poly (ethylene glycol)-co-poly (lactic acid)
[15], a core-shell-type’ polymeric micellar nanoparticle
formulation (NK105) [16,17], poly (ethylene glycol)-
poly(4-(2-vinylbenzyloxy-N-picolylnicotinamide) [18],
poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolac-
tone) [19], poly (lactic acid)-poly (ethylene oxide)-Arg-
Gly-Asp [20], and triblockpolylactic acid (PLA)- poly-
ethylene glycol(PEG)-PLA [21]. For instance, polymeric
micelle-entrapped PTX (Genexol-PM) has recently
been approved for clinical use [22-24]. This micellar
nanostructure is not aggregated or taken up by reticu-
loendothelial system (RES).
Having considered the biocompatibility of polyur-
ethane polymers and their wide applications in biomedi-
cal consumption [25,26], in the current work, we
synthesized a novel waterborne polyurethane micellar
nanoformulation and studied its potential for delivery of
PTX in the human breast cancer MCF-7 cells.
Results
Spectrophotometric characterization of PUD
We used an optimized synthesis methodology for pro-
duction of polyurethane dispersion (Figure 1). The
structure of the prepared phenol blocked polyurethane
dispersion (PBPUD) was confirmed by FTIR spectro-
scopy (Figure 2A). The absence of characteristic NCO
absorption around 2270 cm
-1 indicates the absence of
free NCO groups. These data suggest that the NCO
groups were effectively blocked by phenol. Strong
absorptions at 1731 cm
-1 (C = O stretching of urethane
and carboxylic groups), 2850 and 2939 cm
-1 (CH2
stretching vibrations of PTMEG and TDI), 1112 cm
-1
(C-O-C stretching vibration of PTMEG), 3288 cm
-1 (N-
H stretching), 1533 cm
-1 (N-H bending) and 1210-1240
cm
-1 (the stretching vibration of the C = O group
combined with the N-H group) confirmed the PBPUD
formation.
In
1HNMR spectrum of polyurethane, the internal
methylene groups of PTMEG and methyl groups of
triethylammonium moieties were detected at 1.59 ppm.
The CH3 g r o u po fT D Iw a so b s e r v e da t2 . 1 4p p m .T h e
groups attached to etheric oxygen atom and methylene
groups of triethylammonium moieties appeared at 3.32-
3.53 ppm. The peaks at 4.13 and 4.31 ppm represent
methylene groups of PTMEG and DMPA moieties con-
nected to urethane oxygen atom. Multiplet peak
observed at 6.78-7.73 ppm was attributed to aromatic
protons of TDI and phenol, as well as urethane NH
groups (Figure 2B).
Size, size distribution and zeta potential analysis
As shown in Table 1, the average hydrodynamic dia-
meter of PTX loaded micelles and their polydispersity
were respectively 50.3 ± 1.3 nm and 0.074 ± 0.006 nm,
while they showed average zeta potential about -42.98 ±
1.53 mV. The pyrene partition study displayed a CMC
value of 0.2 mg/L for PUD polymer in aqueous solutions
(Table 1). These nanostructures retained their average
size and polydispersity over 9-day incubation period at
room temperature (Figure 3).
Drug release profile and kinetics
The capability of PUD nanomicelles to solubilize PTX in
aqueous media was investigated using different ratios of
drug to polymer. All the prepared solutions were clear
opalescence, up to a certain ratio, and then precipitation
was evident by visual inspection. The maximum solubili-
zation of PTX occurred when the drug to polymer ratio
was 1 (wt) to 1.25(%). At higher ratios, the solubility
appeared to be lower. The maximum calculated loading
content of PTX in PUD micelles was 80% (1 mg PTX
per 1.25 mg polymer).
As shown in Figure 4, PTX release from polymeric
micelles (over a 72 h period) was slower at pH 7.4 as
compared to pH 5.4 (one-way ANOVA, P < 0.05). Com-
parison of the release profiles of free PTX revealed simi-
lar release profiles at pH 7.4 and 5.4 (f2 > 50). Under
the studied conditions, 67.46% and 98.8% of physically
loaded paclitaxel was released at pH 7.4 and 5.4, respec-
tively (Figure 5). As shown in Table 2, the kinetic analy-
sis of drug release data revealed that the release of PTX
from nanomicelles was best fitted by Higuchi model (R
2
= 0.99), implying superiority of diffusion process [27].
MTT assay
The MTT cytotoxicity assay showed cell viability
changes in direct correlation with the concentration of
both free paclitaxel and its polymeric formulations. As
s h o w ni nF i g u r e6 ,i nc u l t u r e dM C F - 7c e l l s ,t h eP T X
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free PTX (IC50 for MCF-7 cells is 4.2 nM) after 48 h
incubation, while no noticeable cytotoxicity was
observed for polymer itself at concentration used for the
formulation of nanomicelles.
Real time PCR assessment
As shown in Figure 7A, the expression of CYCS gene
was not significantly altered by polymer or PTX, but sig-
nificantly changed (upregulated) by the PTX loaded
nanomicelles. The expression of CASP3 and CASP9
genes were altered (upregulated) in the cells treated
with PU polymer itself and the PTX loaded nanomi-
celles after 48 h (Figures 7B and 7C). The expression of
STAT1 gene was significantly upregulated in the cells
treated with the PTX loaded nanomicelles, PTX and PU
polymer (Figure 7D), while the expression of the metas-
tasis inducer gene “CTTN” was significantly downregu-
lated in all the treated cells as compared to the
untreated control cells (Figure 8).
Comet assay
The comet assay was performed to detect possible DNA
damage in the cells treated with the PTX loaded nano-
micelles [28,29]. Figure 9 shows the comet assay for
assessment of DNA integrity in the MCF-7 cells treated
with the PTX loaded nanomicelles. The treated MCF-7
cells with polymer or PTX revealed no significant DNA
fragmentation, but those cells treated with the PTX
loaded nanomicelles showed DNA fragmentation.
Discussion
The main objective of this research was to develop enzy-
matically bioactive polymeric nanomicelles for solubili-
zation and efficient transportation of anticancer
chemotherapies into cancer cells. To pursue such aim,
we synthesized novel waterborne polyurethane with abil-
ity to form stable nanomicelles in aqueous media. The
polymeric matrix was prepared based on commonly
used method for preparation of waterborne polyur-
ethane through introduction of anionic carboxylate ion
Figure 1 Synthesis scheme of polyurethane dispersion.
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of polymeric aqueous solution and controlling the mole-
cular weight of polymer, the block ratio of OH and
NCO containing moieties was adjusted to less than 1,
and subsequently the free terminal NCO groups were
blocked with phenol blocking agent. To the best of our
knowledge, this is the first report on utilization of this
polymeric nanocarrier for encapsulation and delivery of
PTX. We speculate that the PTX loaded nanomicelles
are less viable for uptake by RES. Thus, longer
Figure 2 FTIR (A) and
1HNMR (B) spectra of PUD.
Table 1 Physicochemical characteristics of PUD micelles
Polymer Average micellar size (nm) Polydispersity (nm) CMC (mg/l) Zeta potential (mV)
PUD 50.3 ± 1.3 0.074 ± 0.006 0.2 ± 0.03 -42.98 ± 1.53
Data represent mean values ± standard deviation (SD).
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greater EPR effects in tumor microenvironment are
expected. And since the cosolvent mediated toxicity has
been resolved, higher doses of PTX can be administered
using these nanomicelles.
Having possessed suitable negative zeta potential
charge, the PTX loaded PU based nanomicelles dis-
played no aggregation and lower level of CMC (Table
1). It has previously been reported that negatively
charged nanoparticles can significantly internalize by the
primary human alveolar immortal AT1 cells [30].
Further, hydrophilic nanomicelles were shown to stay in
blood stream as long circulating drug delivery system
[31,32], during which period the entrapped drug mole-
cules can be protected from biological impacts (e.g., glo-
merular excretion, enzymatic degradation) and
recognition of nanomicelles by RES. Also, the hydrophi-
lic nanoparticles in range of 50-200 nm are deemed to
be less prone to such biological impacts. The PTX
loaded nanomicelles in our study displayed similar size
range (~50 nm) (Table 1), and resulted in high physical
stability without aggregation and/or sedimentation at
room temperature for 9 days (Figure 3). The drug load-
ing efficiency of the PTX loaded PU based nanomicelles
was about 80%, demonstrating their higher drug encap-
sulation capacity. It should be stated that the high load-
ing efficiency is generally considered as an advantage for
the amphiphilic polymeric carriers because of reserving
high amount of hydrophobic drug in hydrophobic core
of micelle leading to an increased solubility of drug in
aqueous media [33]. Our findings appeared to be some-
what similar to the results obtained from pluronic P105/
L101 mixed polymeric micelles [34], however the
smaller size of the PU based nanomicelles (i.e., 50 nm
vs. 185 nm) may result in more efficient EPR effects.
Ideally, a minimal leakage of the loaded drugs from
drug nanocarriers should occur during circulation of the
nanocarriers in blood stream. However, once taken up
by cells, such nanocarriers should liberate the loaded
drugs in the cytosol of the target cells to warrant the
efficiency of chemotherapy. The release of drugs from
pH-sensitive polymeric nanocarriers were shown to be
triggered by the lower pH of the endosomal compart-
ments [35]. Furthermore, biodistribution of pH-sensitive
polymeric nanomicelles were shown to possess signifi-
cantly longer blood circulation pattern and higher accu-
mulation of drugs in solid tumors [35]. We looked at
the drug release profiles of the PTX loaded nanomicelles
at two different pH conditions (i.e., pH 7.4 and 5.4) and
witnessed a faster PTX liberation profile at pH 5.5 (Fig-
ure 5). We assume that the ionic structure of PUD may
fail at the lower pH value, per h a p sa sar e s u l to ft r a n s -
formation of carboxylate ionic groups to their acidic
form and subsequent separation of polymeric carrier. In
these nanomicelles, the release of PTX appeared to be
dependent upon both diffusion and biodegradation pro-
cesses. As shown in Figure 3, we monitored the particle
s i z e so v e rt h er e l e a s et i m et oc o n f i r mt h ep o s s i b i l i t yo f
degradation during the release period under an aqueous
condition. The results showed no noticeable changes in
the sizes of the nanomicelles measured by DLS at pH
7.4. This implies that drug release was mainly due to
diffusion at pH 7.4, while diffusion and slight polymer
degradation seemed to be the main mechanism of drug
release at pH 5.4. Among the release kinetics models
used for analysis of data (Table 2), the release of PTX
Figure 3 Average diameter and polydispersity of PUD nanomicelles. Data represent replicates at room temperature.
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(R
2 = 0.99) that describes the release of drugs from
matrix as a square root of time dependent process based
on Fickian diffusion law [27].
The cytotoxicity impacts of paclitaxel, polymeric car-
rier and drug loaded nanomicelles were also studied in
the human breast cancer, MCF-7 cells. The PTX loaded
nanomicelles showed a significant influence on the pre-
vention of cell proliferation as compared to the
untreated control and positive controls (i.e., PTX and
polymers treated cells). Despite biologic impacts of
different polymeric carriers (e.g., polyethylenimine) in
target cells [36], the PU polymer alone showed no cyto-
toxic effects in the treated cells. The PTX alone induced
somewhat cytotoxic effects in the treated cells; however
such cytotoxicity was not comparable to that of the
PTX loaded nanomicelles. Although we did not conduct
a direct examination for the cellular uptake of nanomi-
celles, the cytotoxic effects and the gene expression
changes induced by the PU nanomicelles can presum-
ably indicate high uptake of the PTX loaded nanomi-
celles by the MCF-7 cells. Based upon physicochemical
Figure 4 In vitro release profile of paclitaxel loaded nanomicelles. (A) Drug release profile at pH 7.4. (B) Drug release profile at pH 5.4. All
experiments were performed at 37°C. Data represent mean values ± SD (n = 3).
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that these nanostructures can release the loaded drugs
in the endosomal compartments in a pH-dependent
manner. Similarly, pH-sensitive poly(2-tetrahydropyranyl
methacrylate) [poly(THPMA)] nanospheres have
recently been developed and shown higher cellular
uptake potential with a pH-dependent release of the
loaded drug (PTX) [37]. Micellar formulation of PTX
using cholesterol-grafted poly(N-isopropylacrylamide-co-
N, N-dimethylacrylamide-co-undecenoic acid) was
reported to provide nanomicelles (~220 nm) with low
CMC (~ 20 mg/L) and fast liberation of drug at pH 5.0
[38]. These PTX loaded nanomicelles were shown to
induce toxicity against KB cells, in which a receptor-
mediated endocytosis process was responsible for nano-
micelles transportation [38]. Given the fact that enzy-
matic oxidation is the primary mechanism of
biodegradation of the PU based nanomicelles [39], the
PTX loaded nanomicelles used in our study may func-
tion as safer long circulating nanocarriers with ability of
drug liberation into the cytosol.
To reveal the cytotoxic mechanism(s) of the PTX
loaded nanomicelles, we looked at the gene expression
profile of some pivotal genes related to apoptosis, in
which the death signal is generated inside the cell after
a chemical treatment leading to release of mitochondrial
factors such as cytochrome c into the cytosol. The
Figure 5 Comparison of paclitaxel release profiles from nanomicelles at pH 7.4 and 5.4. For comparison similarity factor (f2) was used. **
represents significant difference between two pH conditions (f2 < 50).
Table 2 The release kinetics models of paclitaxel from
nanomicelles at pH 7.4 and 5.4
Model name Model R
2 reference
pH
7.4
pH
5.4
First order ln (1-F) = - kft 0.974 0.780 [53]
Higuchi model F=K H
√
t 0.990 0.984 [52,54]
Korsmeyer
model
ln F = lnkp + plnt 0.948 0.936 [54]
Hixson-Crowell 1 −
3 √
1 − F=K 1/2 t 0.985 0.899 [27]
Weibull ln[-ln(1-F)] = - bln td + blnt 0.974 0.780 [52,54]
Reciprocal
powered time 1
F
− 1=
m
tb
0.947 0.973 [52]
More details on kinetic models for liberation of drugs from nanoparticles can
be found in our previously published paper, see [52].
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gers caspase 9. This complex is called apoptosome and
it acts as a holoenzyme resulting in caspase 9 activation
and finally leading to caspase 3 activation [40,41]. Thus,
the release of cytochrome c into the cytosol of the target
cells can basically be considered as a key regulatory step
than can irreversibly coerce cells to commit an intrinsic
apoptosis [42]. The STAT1 gene is represented by an
anti-proliferative effect and consequent extrinsic apopto-
sis. Subsequent studies have shown that the STAT1 acti-
vates transcription of the CASP1 gene, a member of the
protease family producing apoptosis and, in addition,
activates transcription of the genes FAS and FASL, acti-
vators of the caspase system [43,44]. In our study, we
examined the expression of some of these genes and
witnessed significant overexpression of the genes stu-
died (i.e., CYCS, CASP3, CASP9 and STAT1) in the
treated cells with the PTX loaded nanomicelles even
after 48 h. Interestingly, the expression of CYCS was
not affected by the polymer itself as compared to the
untreated control cells, which may be assumed as lack
of intrinsic toxicity of polymer alone. However, STAT1
gene was somewhat overexpressed in the treated cells
with the polymeric nanocarrier compared to the
untreated control cells. We also observed overexpres-
sion of CASP3 and CASP9 induced by the polymer
itself, which was not surprising since the overexpression
of CASP3 and CASP9 genes may occur via CASP1
pathway activated by STAT1 gene (Figure 7). It should
also be stated that a urethane compound diethyl-4,4’-
methylenebis (N-phenylcarbamate) was shown to induce
inhibitory effects on tubulin polymerization in the Chi-
nese hamster cell lines (CHL and V79) and a human
cancer cell line (HeLa S3), causing mitotic arrest even
greater than that of PTX and colchicine and eliciting
chromosome aberrations [45].
To examine possible DNA fragmentation, the comet
assay was exploited with results showing significant
DNA refraction in the treated cells with the PTX loaded
nanomicelles (Figure 9). We speculate that the fragmen-
tation of DNA occurs indirectly as a result of activation
of apoptosis pathways and/or perhaps direct interaction
of these nanomicelles with subcellular elements such as
tubulin and DNA itself.
Metastasis in cancerous cells appears to be a crucial
problem for cancer therapy. Thus, the impact of nano-
formulations should be examined regarding their possi-
ble potential for induction of inadvertent intrinsic
metastasis. To pursue this concept, we looked at the
expression pattern of the CTTN gene (cortactin) which
is an important gene for promoting lamellipodia and
invadopodia formation as well as cell migration [46,47].
We found downregulation of CTTN gene in the treated
cells with the PTX loaded nanomicelles (Figure 8),
which may be considered as further indication for the
safety of the PTX loaded nanomicelles from this point
of view.
Conclusion
To develop bioactive biocompatible nanomicelles for
delivery of anticancer agents such as paclitaxel, an oxi-
datively biodegradable polyurethane polymer was
Figure 6 In vitro cytotoxicity of polymer, free paclitaxel and PTX loaded nanomicelles in MCF-7 cells. Data represent cell viability of the
treated cells after 24 and 48 h. Con: control, P: polymer, PTX: free paclitaxel (IC50, 4.2 nM), PLNM: paclitaxel loaded nanomicelles (included
moiety of IC50 paclitaxel).
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taining PTX. The PU nanomicelles showed considerably
appropriate physicochemical (e.g., ~50 nm in diameter,
0.2 mg/L CMC, suitable negative zeta potential charge,
high stability, very low aggregation, high loading effi-
ciency, and pH-sensitivity for PTX release) and biologi-
cal (e.g., gene expression alterations) properties. The
PTX loaded nanomicelles were significantly taken up by
the MCF-7 cells resulting in significant activation of
important genes related to the cell death program such
as cytochrome c. Based upon these findings, the self-
assembled waterborne polyurethane nanomicelles may
be considered as an appropriate drug delivery nanocar-
rier candidate for further translational investigations.
Methods
Materials
Poly(tetramethylene ether) glycol (PTMEG, OH func-
tionality = 2.0, Mn: 2000 g mol
-1), imethylol propionic
acid (DMPA), RPMI 1640 complete growth media, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT), normal melting point agarose, low melting
point agarose, fetal bovine serum, paclitaxel, penicillin,
streptomycin and TRI Reagent
® were obtained from
Sigma-Aldrich Chemical Co. (Poole, UK). Toluene diiso-
cyanate (TDI mixture of 2,4 and 2,6-isomers), phenol,
triethylamine (TEA) and N-Methyl-2-pyrrolidon (NMP),
dimethyl sulfoxide (DMSO), acetonitrile, pyrene, sodium
salicylate, glycine, NaCl, chloroform, diethylpyrocarbo-
nate (DEPC), Trizma base, Triton-X100, ethylenediami-
netetraacetic acid (EDTA) citrate buffer salts and
phosphate buffer salts were obtained from Merck
(Darmstadt, Germany). Moloney murine leukemia virus
(MMLV) reverse transcriptase, MMLV buffer with
dithiothreitol (DTT) and random hexamer primer were
purchased from Fermentas Life Science (Burlington,
Canada) and Brilliant
®SYBR
® Green I PCR master mix
was prepared from Stratagene (La Jolla, CA, USA).
Figure 7 Apoptosis related gene expression ratio in treated and untreated control cells. (A-D) genes expression ratios of CYCS, CASP3,
CAS9 and STAT1, respectively. Con: control, P: polymer, NP: paclitaxel loaded nanomicelles (included equal IC50 paclitaxel), PTX: free paclitaxel
(IC50, 4.2 nM).
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PTMEG (0.06 mol, dried at 80°C under vacuum for 24
h) and DMPA (0.06 mol) in equal weight of NMP
were placed into a four-necked reaction kettle
equipped with a mechanical stirrer, heating mantle,
reflux condenser, dropping funnel and N2 inlet and
outlet. The reaction mixture was stirred at 75°C under
N2 atmosphere. After complete mixing, vacuum distil-
lation purified TDI (0.16 mol) was dropped into the
reactor at such a rate that the reaction temperature
would not surpass 75°C. The temperature was then
increased to 85°C and the reaction was continued till
the NCO content reached the theoretical value as
determined by dibutyl amine back titration method.
Then the reaction mixture was cooled down to 60°C
and followed by the slow addition of phenol (0.08 mol)
diluted with acetone (150 ml). The reactions were car-
ried out until NCO peak disappeared in the FTIR
spectrum. The blocked polyurethane pre-polymers
were cooled to 50°C and the neutralizing agent, TEA
( 0 . 0 6m o l )w a sa d d e da n da l l o w e dt or e a c tt of o r m
ionomer for 30 min. Finally, DD water was added to
accomplish the dispersion under vigorous stirring. A
uniform PUD was obtained, from which the acetone
was removed under low vacuum at 60°C. The final
solution was diluted with water in a way that each ml
of solution contains 125 mg PU. The scheme of these
reactions is illustrated in Figure 1.
Characterization of PUD
PUDs were characterized by spectroscopic methods.
Fourier transform infrared (FTIR) spectra were obtained
using Bruker IFS 48 instrument (Bruker Optik GmbH,
Germany). All spectra were taken under air as a func-
tion of time with 16 scans at a resolution of 4 cm
-1 and
a spectral range of 4000-5000 cm
-1. Nuclear magnetic
resonance (
1HNMR) spectra were recorded on a Bruker
model AVANCE DPX 400 MHz instrument (Bruker
Optik GmbH, Germany) with CDCl3 as solvent. Spectra
were averaged from 8 transients and calibrated by pro-
ton lock method.
Physical encapsulation of paclitaxel into PUD
Sonication method was used to prepare waterborne
polyurethane nanomicelles with highly loaded PTX. For
this purpose, PTX (0.1-1.25 mg) was dissolved in
DMSO (25 μl) and added to the fixed concentration of
polymer in the deionized water (1.25 mg per each ml of
solution). The mixture was sonicated (at 250 kJ) for 10
sec. This colloidal solution was then centrifuged at
21000 × g (SIGMA Laborzentrifugen GmbH, Germany)
for 10 min to remove free, unloaded PTX molecules.
The supernatant solution was analyzed for paclitaxel
content using Pharmacia Biotech HPLC system (San
Francisco, CA, USA) equipped with C18 Column (4.6 ×
250 mm, 5 μm). The mobile phase was acetonitrile/H2O
(60:40) with flow rate of 1.0 ml/min and injection
Figure 8 Metastasis inducer gene (CTTN) expression ratio in treated and untreated control cells. Con: control, P: polymer alone, NP:
paclitaxel loaded nanomicelles (included equal IC50 paclitaxel), PTX: free paclitaxel (IC50, 4.2 nM).
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Page 10 of 15Figure 9 DNA fragmentation by comet assay in treated and untreated control cells. (A) Treated cells with PTX loaded nanomicelles. (B)
Treated cells with PTX. (C) Normalized percentage of DNA fragmentation. Con: control, P: polymer, NP: paclitaxel loaded nanomicelles, PTX: free
paclitaxel.
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plished at 227 nm. The PTX loading rate (w/w %) and
the encapsulation efficiency (w/w %) were calculated as
previously described [48].
Determination of critical micelle concentration (CMC)
A change in the fluorescence excitation/emission spectra
of pyrene in the presence of designated concentration of
the PUD was used to measure the CMC according to a
method described previously [49]. Briefly, pyrene was
dissolved in DMSO to provide a final concentration of 6
×1 0
-7 M. Aqueous polymeric solutions with concentra-
tion ranging from 0.1-1.5 mg/L were then added and
samples were sonicated for 10 sec, just before the fluor-
escence emission measurements. The excitation spec-
trum of pyrene for each sample was obtained at room
temperature using Perkin Elmer LS55 fluorescence spec-
trophotometer (Perkin Elmer, Rockville, USA). The
emission wavelength and the excitation/emission slit
were set at 390 nm and 5 nm, respectively. The quench-
ing intensity of the emission peak at 394 nm was plotted
against various polymer concentrations. The CMC was
measured from a decrement emission intensity peak
(394 nm) at the onset of micellization.
Determination of size and zeta potential of micelles
The average diameter, size distribution and zeta poten-
tial of the prepared nanocarriers were estimated by
dynamic light scattering (DLS) using Brookhaven Zeta
PALS (Brookhaven Instruments Corporation, Austin,
USA) after centrifugation at 21000 × g,p H7 . 4f o r1 0
min (SIGMA Laborzentrifugen GmbH, Germany).
Evaluation of the physical stability of nanocarrier
PTX loaded PUD micellar solution (1 mg/ml) was prepared
in phosphate buffer (0.01 M, pH 7.4) and left for 9 days at
room temperature. At different time points, the hydrody-
namic diameter and the polydispersity of the micellar solu-
tion was assessed using Brookhaven Zeta PALS
(Brookhaven Instruments Corporation, Austin, USA).
Determination of paclitaxel release profile from polymeric
micelles
The amounts of PTX released from loaded micelles were
determined using phosphate buffer (0.01 M, pH 7.4) and
citrate buffer (0.01 M, pH 5.4) containing 2 M sodium
salicylate at 37°C [50,51]. The experiments were initiated
by adding free or micellar PTX solution to the buffer to
provide a final concentration of 0.5 mg/ml of PTX. Then,
5 ml of the micellar solution was transferred into a dialy-
sis bag (Spectrapor, MW cutoff 3500 gmol
-1) and placed
into 500 ml of phosphate buffer (0.01 M, pH 7.4) and
citrate buffer (0.01 M, pH 5.4). The release study was
performed at 37°C using a shaking water bath (GFL,
Burgwedel, Germany). At the designated time intervals,
considering sink condition, sampling was performed. In
each time point, 30 μl of sample was withdrawn, freeze
dried and dissolved in 60 μl of methanol. Then, 20 μla l i -
quot was injected into HPLC to determine the quantity
of released PTX. The accumulated release was calculated
using following equation:
R =
V
n−i
i Ci + Vo Cn
mdrug
Where, R is the accumulated release (%), V is the
sampling volume, V0 is the initial volume, Ci and Cn are
the paclitaxel concentrations, i and n are the sampling
times, and mdrug is the mass of paclitaxel in PUD
nanomicelles.
The release profiles were compared using similarity
factor f2. The profiles were significantly different when
f2 was less than 50 as described previously [28]. Various
important kinetic models (Table 2) were exploited to
address the release pattern of the PTX from nanomi-
celles as we described previously [52].
In vitro toxicity of paclitaxel loaded PUD micelles
MTT assay was recruited for cytotoxicity assessment of
PTX loaded PUD micelles in human breast cancer,
MCF-7 cells. Briefly, cells were cultured at a seeding
density of 4.0 × 10
4/cm
2 in 96-well microplate. The cul-
tivated cells were maintained in a humidified atmo-
sphere (5% CO2/95% air) at 37°C with medium
comprising of RPMI 1640 complete growth media sup-
plemented with 10% FBS, 100 units/ml penicillin and
100 μg/ml streptomycin. At 50% confluence (24 h post
seeding), the cultured cells were treated with several
concentrations of PTX loaded (2.1 nM) and unloaded
nanomicelles as well as free PTX (IC50, 4.2 nM) over
different incubation periods (24 and 48 h). Then the
medium was replaced with 200 μl fresh media contain-
ing 50 μl of MTT solution (5 mg/ml in PBS) and the
cells were incubated for an additional 4 h at 37°C. After
incubation period, the media/MTT mixture was care-
fully removed and 200 μl of DMSO plus 25 μl of Soren-
son’s glycine buffer (0.1 M glycine, 0.1 M NaCl, pH
10.5) were added to each well. The absorbance of each
well was measured after 10 second shaking, employing a
microplate reader ELX808 (Bioteck, Vermont, VT, USA)
at 570 nm. The mean and standard deviation values for
each treatment were determined and converted to the
percentage of viable cells relative to the control.
Quantitative real time PCR
Total RNA extraction
For RNA analysis, MCF-7 cells were lysed using TRI
Reagent
® according to manufacture guidelines. In brief,
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cells were lysed by adding desired amount of TRI
Reagent
® (2 ml per 25 cm
2 T-flask). The lysates were
homogenized and transferred to RNAse/DNAse-free
microtubes. Chloroform (0.2 ml per each ml of TRI
Reagent™ used for lysing) was added to each sample,
and the mixture was vortexed. After maintaining at
room temperature for 5 min, the samples were centri-
fuged at 12000 × g, 4°C and 10 min and the colorless
upper aqueous phase was carefully separated and mixed
with ice-cold iso-propanolol (0.5 ml per each ml of TRI
Reagent
® used initially). The mixture was centrifuged at
12000 × g, 4°C for 10 min, yielding total RNA pellet
that was washed with 75% ethanol (×3). The air dried
samples were dissolved in DEPC treated water and
tested qualitatively and quantitatively prior to its use for
RT-PCR experiments.
RT reaction and cDNA preparation
The isolated RNA was reverse transcribed to cDNA
using MMLV reverse transcriptase. For RT reaction, 1
μlR N A( 1μg/μl) was mixed with master mix [DEPC
treated water 13 μl, dNTP’s (10 μM) 2 μl, MMLV buffer
with DTT 2 μl, random hexamer primer (pdN6; 400 ng/
μl) 0.5 μl], and denatured at 95°C for 5 min. The sample
was then cooled down to 4°C for 5 min using ice-bath.
Then 1 μl MMLV (200 U/μl) and 0.5 μlR N a s i n( 4 0U /
μl) were added to the sample and the mixture was incu-
bated using following thermocycling program: 10 min at
25°C, 42 min at 42°C, and 5 min at 95°C. The prepared
cDNA templates were used for real time PCR
experiments.
Real time PCR
Primers were designed from published Gene Bank
sequences using Beacon Designer 5.01 (Premier Biosoft
International, http://www.premierbiosoft.com) and listed
in Table 3. All amplification reactions were performed
in a total volume of 25 μl using iQ5 Optical System
(Bio-Rad Laboratories Inc., Hercules, USA). Each well
contained: 1 μlc D N A ,1μl primer (100 nM each
primer), 12.5 μl 2× Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, USA), and 10.5 μl
RNAse/DNAse free water. Thermal cycling conditions
were as follow: 1 cycle at 94°C for 10 min, 40 cycles at
95°C for 15 sec, 56-62°C (annealing temperature, see
Table 3 for details) for 30 sec, and 72°C for 25 sec.
Interpretation of the result was performed using the
Pfaffle method and the threshold cycle (Ct) values were
normalized to the expression rate of GAPDH as a
housekeeping gene. All reactions were performed in tri-
plicate and negative controls were included in each
experiment.
Comet assay
To detect possible DNA damage, the comet assay was
carried out. Prior to the comet assay, the trypan blue
based viability test was performed to ensure about the
viability of cells (> 70%) [28,29]. Briefly, the slides were
precoated with normal melting point agarose (1% in
PBS; 0.1 M and pH 7.2) and dried at room temperature.
Cells (5.0 × 10
5/mL) were mixed with low melting point
agarose (0.5% in PBS; 0.1 M, pH 7.2 and 37°C) and one
drop of mixture was placed on precoated slide and cov-
ered with lamella. The slides were kept in a freezer (-20°
C) for 10 min and then placed in lysis buffer (NaCl 2.5
M ,E D T A1 0 0m M ,T r i z m ab a s e1 0m M ,T r i t o nX - 1 0 0
1%, DMSO 10%, pH 10, and 4°C) for 4 h. The slides
were washed with distilled water (×3) and placed in con-
tractive buffer (Tris base 0.4 M and pH 7.5) for 10 min,
and then in electrophoresis buffer (30 ml NaOH 10 N
and 5 ml EDTA 200 mM in 1 L distilled water; pH 13)
for 20 min. The slides were electrophoresed at 25 A and
300 mV condition for 40 min using electrophoresis buf-
fer, then placed in staining buffer (ethidium bromide
0.02 mg/ml) for 5 min and washed (×3) with distilled
water. The fluorescent images were obtained using
Olympus IX81 microscopes (Olympus Optical, Tokyo,
Japan) and DNA damage was quantified using Casp
software (CaspLab, University of Wroclaw, Institute of
Theoretical Physics).
Table 3 Real time PCR genes and their forward/reverse primers
Gene name & Accession No Primer sequence Tm (°C) Ta (°C) Size (bp)
GAPDH
(NM_002046.3)
F:5’-AAGCTCATTTCCTGGTATGACAACG-3’
R:5’-TCTTCCTCTTGTGCTCTTGCTGG-3’
61.3
62.4
59 126
CASP3
(NM_004346.3)
F: 5’-TGCCTGTAACTTGAGAGTAGATGG-3’
R: 5’-CTTCACTTTCTTACTTGGCGATGG-3’
61
61
56 172
CYCS
(NM_018947.4)
F: 5’- ACCTTCCATCTTGGCTAGTTGTG-3’
R: 5’- ATCGCTTGAGCCTGGGAAATAG-3’
59.3
59
58 129
CASP9
(NM_001229.2)
F: 5’- TGCTGCGTGGTGGTCATTCTC-3’
R: 5’- CCGACACAGGGCATCCATCTG-3’
61.8
63.7
62 94
STAT1
(NM_007315.3)
F: 5’- TCATCAGCAAGGAGCGAGAG-3’
R: 5’- TCAGGGAAAGTAACAGCAGAAAG-3’
59.4
58.9
56 196
CTTN
(NM_005231.3)
F: 5’- GCCGACCGAGTAGACAAGAGC-3’
R: 5’- ATTTGCCGCCGAAACCTTTGG-3’
63.7
59.8
59 100
Tm: Melting temperature; Ta: Annealing temperature
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One way ANOVA with an appropriate multiple-compar-
ison test or Student’s t-test were employed for statistical
analysis using SPSS and MSTATC. A p-value less than
0.05 was considered statistically significant. Data were
represented as mean ± standard deviation (SD) of triple
measurements.
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